Inflammation plays a key role in many neurological diseases, making them difficult to diagnose and treat. Triggers like infection, brain injury, toxic metabolites, or autoimmunity complicate disease tracking and treatment.
With a drug development failure rate over 90%, due in part to complex disease mechanisms and inadequate preclinical models, there is a critical need for blood-based biomarkers. Antibody profiling offers promising diagnostic and patient stratification tools, especially in neurological diseases with inflammatory or autoimmune components.
